Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
This study has been completed.
Study NCT00608907 Information provided by Millennium Pharmaceuticals, Inc.
First Received on January 23, 2008. Last Updated on January 26, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
Neoplasms, Plasma Cell
More general conditions related to this trial
Blood Protein Disorders
Immune System Diseases
Neoplasms by Histologic Type
Interventions listed in this trial
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Antineoplastic Agents, Hormonal
Central Nervous System Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Peripheral Nervous System Agents
Physiological Effects of Drugs
Sponsors listed in this trial
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers